ForPatients
by Roche

Age-Related Macular Degeneration Geographic Atrophy

A study to look at how safe a study medicine was for patients – when taken at different doses - and how this medicine was processed through the body

Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Trial Status	Trial Runs In	Trial Identifier
Completed	1 Countries	NCT03295877 GR39821

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This Phase 1, open-label, multicenter study will investigate the safety and tolerability of RO7171009 following single and multiple intravitreal (ITV) administrations in patients with GA secondary to AMD. The study consists of two stages: Single Dose-Escalation (SAD) and Multiple-Dose (MD) stages.

Genentech, Inc.
Sponsor

Phase 1
Phase

NCT03295877 GR39821
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>= 50 Years	No

This was a study to investigate a new medicine (FHTR2163) in patients with an eye disease, called “age-related macular degeneration with geographic atrophy”, or “AMD with GA”. Patients were injected in their eye with different amounts of the study medicine to find the dose that was safe.